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A B S T R A C T
The oral S1PR1 agonist ponesimod demonstrated substantial eﬃcacy in a phase II clinical trial of psoriasis.
Unfortunately, systemic side eﬀects were observed, which included lymphopenia and transient bradycardia. We
sought to develop a topical soft-drug S1PR1 agonist with an improved therapeutic index. By modifying pone-
simod, we discovered an ester series of S1PR agonists. To increase metabolic instability in plasma we synthesised
esters described as speciﬁc substrates for paraoxonase and butyrylcholinesterases, esterases present in human
plasma.
Introduction
Psoriasis is a common chronic inﬂammatory skin disease that aﬀects
2% of the population.1 52.3% of patients were dissatisﬁed with current
treatments in a recent survey from the National Psoriasis Foundation in
the US.1 Recently approved biological drugs targeting disease relevant
receptors, such as secukinumab2 or ixekizumab3 for interleukin (IL)-17
and ustekinumab for IL-12/234 have brought great beneﬁt to patients
with severe symptoms of the disease. However, a need remains for safe,
convenient, eﬃcacious therapies for mild and moderate psoriasis.
Sphingosine-1-phosphate receptor (S1PR) agonists are of interest to
the pharmaceutical industry, due to their potential to treat diseases of
the immune system such as psoriasis and multiple sclerosis as well as
cancer.5,6 S1PR agonists, such as ﬁngolimod and ponesimod (Fig. 1),
initially activate sphingosine-1-phosphate receptors, but subsequently
trigger receptor internalisation. This shuts down the sphingosine 1-
phosphate signalling pathway, which then prevents the maturation and
migration of lymphocytes.7 In 2010 ﬁngolimod was approved for the
treatment of relapsing/remitting multiple sclerosis and is the only
S1PR1 agonist approved to date.8
In a phase 2 study in plaque psoriasis, a 40mg oral dose of pone-
simod, led to a 75% reduction in psoriasis area and severity index
(PASI) score in 77% of the patients.9 This level of eﬃcacy is competitive
with other small molecules in development to treat psoriasis (apremi-
last10, tofacitinib11 and sotrastaurin12). Ponesimod was not however
progressed into phase 3, possibly due to safety concerns. Oral use of
pan-S1PR and S1PR1 selective modulators is associated with several
severe side eﬀects such as lymphopenia, bradycardia and dyspnoea,
which limits their utility as therapies for non-life threatening chronic
diseases.5
In mice, topical application of the S1PR agonist ﬁngolimod led to a
reduction in the number of Langerhans cells migrating to the lymph
node.13 Work by Griﬃths and co-workers has shown that Langerhans
cell migration is higher in involved areas of patient’s skin than in non-
involved areas of skin.14,15 We hypothesised that local inhibition of
Langerhans cell migration, through the eﬀects of topical S1PR agonists,
could restore a normal skin phenotype to patients with psoriasis.
Due to the potential of S1PR agonists to act as eﬃcacious therapies,
for the treatment of psoriasis, we decided to embark on developing a
topical S1PR1 modulator using a fast-follower approach, inspired by
ponesimod. Topical therapies apply drugs directly to the site of action
and can lead to a reduction in the systemic exposure of a drug when
compared to oral dosing. However, due to the chronic nature of psor-
iasis and the need to be able to treat large body surface areas (> 10%),
there is a danger that topical application could lead to biologically re-
levant systemic drug concentrations. To maximise the therapeutic index
we decided to develop a soft drug.16,17 Soft drugs are locally active, in
this case in the skin, but then undergo rapid systemic metabolism, to
metabolites, which are either inactive or rapidly cleared from the sys-
temic circulation.18
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Esters can be metabolised in liver by esterases and cytochrome P450
enzymes.19 However, most tissues are capable of metabolising an ester.
Importantly, human blood contains a wide range of esterases and the
rate of ester hydrolysis in blood can lead to ultra-rapid clearance,20
what we term a super-soft drug. Because S1PR agonists induce transient
bradycardia, and as blood returning to circulation from skin passes
through the heart before reaching the liver, we felt that a very rapid
blood clearance mechanism could potentially discharge the cardio-
toxicity risk. To select compounds which would be likely to demon-
strate the desired pharmacokinetic proﬁle, we targeted a human plasma
stability half-life of < 5min. We chose to ﬁrst develop benzoate ester
analogues of ponesimod to determine if they could demonstrate po-
tential as super-soft drugs. The desired compound would have S1PR
pXC50 of > 7 and a logP in the range of 2–4 which is believed to be
optimal for skin penetration.21
Compounds 4a and 5a–d were synthesised as shown in Scheme 1.
The (Z)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one core 2 was syn-
thesised utilising a one-pot, two step reaction. Only the Z isomer was
observed. N-propylamine was reacted with 1-isothiocyanato-2-methyl-
benzene 1 to give the resulting thiourea, which was condensed with 2-
bromoacetyl bromide followed by addition of pyridine to furnish the
desired thiazolidin-4-one 2. This core was then condensed with the
appropriately substituted benzaldehyde 3a–b to furnish 4a and 5a.
Finally, esteriﬁcation or amidation of 4a gave the desired products.
Based on the conﬁgurational analysis by X-ray, which characterised
crystalline analogues of ponesimod as Z,Z22, all structurally related
compounds 4a, 5a–d, 11, 12a–f and 15a, b were assigned to the Z,Z-
isomer.
We selected human plasma stability as a model for human blood
metabolism. Esters 5a–c and amide 5d demonstrated half-lives of >
180min in human plasma, far greater than the < 5min we were
aiming for. S1PR1 activity was measured using a PathHunter β-Arrestin
recruitment assay.23 All of the ester and amide compounds in Table 1
were active and had pIC50 values ranging from 6.5 to 7.0, with the
exception of compound 5a where a chlorine ortho to the ester provided
100-fold improvement in activity compared to 5b. Gratifyingly, the
parent carboxylic acid 4a, which is the desired metabolite of our esters/
amides was less active, giving a pIC50 of < 6 and meeting our targeted
criteria for producing inactive metabolites.
Aqueous solubility is an important parameter for topically applied
drugs. Increasing aqueous solubility, should directly increase skin pe-
netration rates.24 Increasing aqueous solubility also increases the range
of formulation options that can be used in pre-clinical development. We
were pleased to see that introduction of a hydrogen bond donor at R2 in
5c led to a 4-fold increase in solubility relative to 5b. Changing the
ester linker in 5c to an amide in 5d further improved solubility to >
250 µM, probably due to improvements in lipophilicity (3.4 vs 2.3 re-
spectively).
Encouraged by the solubility and activity data, we focused our ef-
forts on optimising the metabolic proﬁle of the esters. At this time, we
identiﬁed that switching from the o-tolyl group used in ponesimod to an
o-phenol 6 increased aqueous solubility 2-fold, presumably due to the
reduction in lipophilicity (Fig. 2). As 6 was equipotent to ponesimod
(pIC50 7.9) and to maximise compound solubility, subsequent com-
pounds incorporated the o-phenol group.
Compounds 11, 12a–c, 15a and 15b were synthesised using the
route shown in Scheme 2. 12a–c were more soluble than ponesimod,
probably due to signiﬁcant improvements in CHI logD (Table 2). As
expected a clear trend can be seen between low lipophilicity and im-
proved solubility. Homologation of the ester group (15a, b) showed
increased lipophilicity (3.2 and 3.5 respectively) and a commensurate
reduction in solubility. However, as with 5a–d, amide 12a and esters
12b–c also showed a lack of metabolism in our human plasma stability
assay (Table 2).
As simple esters had shown themselves to be stable to human
Fig. 1. Selected S1PR1 modulators.
Scheme 1. Reagents and conditions for preparation of compounds 4a and 5a–d: (a) n-PrNH2 (1 eq), CH2Cl2, rt (b) 2-bromoacetyl bromide (1 eq) and pyridine (2 eq),
CH2Cl2, 0 °C to rt (two steps) (c) aldehyde (1 eq), NaOAc (2 eq), AcOH, 65 °C (d) alcohol (5 eq), HOAt (1.5 eq), EDC (1.5 eq), DIPEA (2.5 eq), CH2Cl2, rt. eq:
equivalent; rt: room temperature; HOAt: 1-Hydroxy-7-azabenzotriazole; EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; DIPEA: N,N-Diisopropylethylamine.
Table 1
Eﬀect of R2 substitution on S1PR1 activity, kinetic aqueous solubility and
human plasma stability.
Compound R1 R2 Kinetic
solubility
(µM)a
CHI logDb S1PR1
pIC50c
H Plasma
Stability
(half-life
min)d
Ponesimod – – 110 3.1 7.9 (0) > 180
5a Cl OMe 39 >4.4 8.6
(0.1)
> 180
5b H OMe 28 >4.4 6.5 (0) > 180
4a H OH 163 1.0 <6
(0)
–
5c H OCH2CH2OH 110 3.4 6.9 (0) > 180
5d H NHCH2CH2OH >250 2.3 7.0 (0) > 180
a The aqueous solubility of the test compounds was measured using laser
nephelometry.
b Reverse-phase HPLC method to determine the chromatographic hydro-
phobicity index (CHI).
c All pIC50s reported in this table correspond to n of 2, reported as their
geometric mean. The range of pIC50 values is provided in brackets.
d Incubated in human plasma at 37 °C.
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plasma, we turned our attention to ester functional groups which had
been shown to be unstable in human plasma in the literature (half-
life < 5min).20 The most successful studies focused on optimising
metabolism by the esterases paraoxonase25 and butyr-
ylcholinesterases26, which are mainly expressed in blood plasma.
We synthesised compounds 11 and 12d–f using the route shown in
Scheme 2, which all contain ester groups that are unstable in human
plasma when attached to other scaﬀolds. Although 12d or 12e did not
show suﬃcient clearance in human plasma we were pleased to identify
compound 12f containing a (2-oxo-1,3-dioxolan-4-yl)methyl ester
which is rapidly degraded in human plasma (Table 3). The half-life of
this ester in human plasma was 9min and metabolite identiﬁcation
conﬁrmed the conversion to the inactive parent acid 11 (Fig. 3).
Unfortunately 12f was also rapidly metabolised in human skin S9
fraction with a half-life of just 23 min, far faster than the desirable half-
life of > 6 h that we target for once daily dosing. In fact, there are
suggestions of a correlation between the relative stability of 12d–f in
human plasma and skin S9 fraction. It may be that the esterases re-
sponsible for the metabolism of 12f are present in both human plasma
and skin S9 fraction or that skin and plasma esterases have similar
substrate aﬃnities. Unfortunately, 12f was also inactive as a S1PR1
modulator (Table 3).
In summary, using a fast follower approach, we identiﬁed a series of
ester S1PR1 modulators. Further optimisation led to improved solubi-
lity and identiﬁcation of ester 12d that is plasma unstable.
Fig. 2. Improvements in aqueous kinetic solubility from introduction of o-
phenol group.
Scheme 2. Reagents and conditions for preparation of compounds 11, 12a–f and 15a, b: (a) n-PrNH2 (1 eq), CH2Cl2, rt (b) 2-bromoacetyl bromide (1 eq) and
pyridine (2 eq), CH2Cl2, 0 °C to rt (two steps) (c) aldehyde (1 eq), NaOAc (2 eq), AcOH, 85 °C (d) BBr3 (8 eq), CH2Cl2, −78 °C to rt (e) For 12a–c. amine (3 eq) or
alcohol (5 eq), HOAt (1.5 eq), EDC (1.5 eq), DIPEA (2.5 eq), CH2Cl2, rt (f) For 12d–f. alcohol, alkyl chloride or alkyl tosylate (1.1–1.5 eq) K2CO3 (1.5 eq), NaI (0.1 eq),
DMF, 70 °C (g) NEt3 (3 eq), EDC (1.1 eq), HOAt (1.1 eq), alcohol (1.5 eq) rt (h) BBr3 (5 eq), CH2Cl2, −78 °C to rt. eq: equivalent; rt: room temperature; HOAt: 1-
Hydroxy-7-azabenzotriazole; EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; DIPEA: N,N-Diisopropylethylamine; DMF: dimethyl formamide.
Table 2
Eﬀect of R1 substitution on kinetic aqueous solubility and human plasma sta-
bility.
Compound n R1 Kinetic
solubility
(µM)a
CHI logDb H Plasma
Stability
(half-life
min)c
Ponesimod – – 110 3.1 > 180
12a 0 NHCH2CONMe2 219 1.9 > 180
12b 0 OCH2CH2CH2OH 183 2.3 > 180
12c 0 OCH2CH(±CH2OH)OH >250 1.8 > 180
15a 1 OMe 155 3.2 > 180
15b 2 OMe 79 3.5 > 180
a The aqueous solubility of the test compounds was measured using laser
nephelometry.
b Reverse-phase HPLC method to determine the chromatographic hydro-
phobicity index (CHI).
c Incubated in human plasma at 37 °C.
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Unfortunately, the ester is inactive and is metabolised in human skin
models. Further eﬀorts will focus on identifying an active, skin stable
compound that is rapidly metabolised systemically will be disclosed in
due course.
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